Literature DB >> 19225040

Different inhibitory effects in rat and human carboxylesterases.

Shiori Takahashi1, Miki Katoh, Takashi Saitoh, Miki Nakajima, Tsuyoshi Yokoi.   

Abstract

In vitro inhibition studies on drug-metabolizing enzyme activity are useful for understanding drug-drug interactions and for drug development. However, the profile of the inhibitory effects of carboxylesterase (CES) activity has not been fully investigated concerning species and tissue differences. In the present study, we measured the inhibitory effects of 15 drugs and 1 compound on CES activity using liver and jejunum microsomes and cytosol in human and rat. In addition, the inhibition constant (K(i) values) and patterns were determined for the compounds exhibiting strong inhibition. Hydrolysis of imidapril and irinotecan hydrochloride (CPT-11) is catalyzed mainly by CES1 and CES2, respectively. In the inhibition study, imidaprilat formation from imidapril in human liver was strongly inhibited by nordihydroguaiaretic acid (NDGA) and procainamide. The inhibition profile and pattern were similar in human liver and rat liver. The compounds showing potent inhibition were similar between liver and jejunum. The K(i) value of NDGA (K(i) = 13.3 +/- 1.5 microM) in human liver microsomes was 30-fold higher than that in rat liver microsomes (K(i) = 0.4 +/- 0.0 microM). On the other hand, 7-ethyl-10-hydroxycamptothecin (SN-38) formation from CPT-11 was not inhibited except by carvedilol, manidipine, and physostigmine. The K(i) value of physostigmine (K(i) = 0.3 +/- 0.0 microM) in human jejunum cytosol was 10-fold lower than that in rat jejunum cytosol (K(i) = 3.1 +/- 0.4 microM) and was similar to that for manidipine. The present study clarified the species differences in CES inhibition. These results are useful for the development of prodrugs.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19225040     DOI: 10.1124/dmd.108.024331

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  16 in total

1.  Prediction and in vitro evaluation of selected protease inhibitor antiviral drugs as inhibitors of carboxylesterase 1: a potential source of drug-drug interactions.

Authors:  Jenna A Rhoades; Yuri K Peterson; Hao-Jie Zhu; David I Appel; Charles A Peloquin; John S Markowitz
Journal:  Pharm Res       Date:  2011-12-09       Impact factor: 4.200

Review 2.  The rationality for using prodrug approach in drug discovery programs for new xenobiotics: opportunities and challenges.

Authors:  Nuggehally R Srinivas
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2011-03-15       Impact factor: 2.441

Review 3.  Regulations of Xenobiotics and Endobiotics on Carboxylesterases: A Comprehensive Review.

Authors:  Yanjiao Xu; Chengliang Zhang; Wenxi He; Dong Liu
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2016-08       Impact factor: 2.441

4.  Human α/β hydrolase domain containing 10 (ABHD10) is responsible enzyme for deglucuronidation of mycophenolic acid acyl-glucuronide in liver.

Authors:  Atsushi Iwamura; Tatsuki Fukami; Ryota Higuchi; Miki Nakajima; Tsuyoshi Yokoi
Journal:  J Biol Chem       Date:  2012-01-31       Impact factor: 5.157

5.  Effects of alcohol on human carboxylesterase drug metabolism.

Authors:  Robert B Parker; Zhe-Yi Hu; Bernd Meibohm; S Casey Laizure
Journal:  Clin Pharmacokinet       Date:  2015-06       Impact factor: 6.447

Review 6.  The role of human carboxylesterases in drug metabolism: have we overlooked their importance?

Authors:  S Casey Laizure; Vanessa Herring; Zheyi Hu; Kevin Witbrodt; Robert B Parker
Journal:  Pharmacotherapy       Date:  2013-02       Impact factor: 4.705

7.  Identification of carboxylesterase-dependent dabigatran etexilate hydrolysis.

Authors:  S Casey Laizure; Robert B Parker; Vanessa L Herring; Zhe-Yi Hu
Journal:  Drug Metab Dispos       Date:  2013-11-08       Impact factor: 3.922

8.  The effect of ethanol on oral cocaine pharmacokinetics reveals an unrecognized class of ethanol-mediated drug interactions.

Authors:  Robert B Parker; S Casey Laizure
Journal:  Drug Metab Dispos       Date:  2009-11-17       Impact factor: 3.922

9.  In vitro metabolism and drug-drug interaction potential of UTL-5g, a novel chemo- and radioprotective agent.

Authors:  Jianmei Wu; Jiajiu Shaw; Sarah Dubaisi; Frederick Valeriote; Jing Li
Journal:  Drug Metab Dispos       Date:  2014-09-23       Impact factor: 3.922

10.  Rapalogues as hCES2A Inhibitors: In Vitro and In Silico Investigations.

Authors:  Cheng-Cheng Shi; Yun-Qing Song; Rong-Jing He; Xiao-Qing Guan; Li-Lin Song; Shi-Tong Chen; Meng-Ru Sun; Guang-Bo Ge; Li-Rong Zhang
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2021-01       Impact factor: 2.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.